ABSTRACT: Backgro und: This study aimed to determine the frequency of transactive response DNA binding protein 43 kDa pathology in PSP, the clinical features of patients with this pathology, and genetic risk factors for it. Methods: Hippocampal sections were screened with immunohistochemistry for transactive response DNA binding protein 43 kDa in 945 PSP cases. A subset of 261 cases that were negative in hippocampus was screened in the amygdala. The density and disruption of this pathology, as well as regional tau burden, and clinical and genetic characteristics were analyzed. Results: We observed transactive response DNA binding protein 43 kDa pathology in 47 cases in the hippocampus and an additional 9 cases that only affected the amygdala. Hippocampal sclerosis was the strongest risk factor, followed by Alzheimer's disease pathology, argyrophilic grain disease, and older age at death. Five stages of transactive response DNA binding protein 43 kDa pathology were identified in PSP: Stage A had pathology only in the amygdala (16%); stage I had pathology confined to the hippocampus and entorhinal cortex (9%); stage II included both regions of stage A and I (38%); stage III spread further to medial occipitotemporal gyrus (20%); and stage IV had pathology in the dorsolateral frontal lobe (18%). Anatomical areas vulnerable to PSP pathology had varying degrees of this pathology in stage II and later. PSP with transactive response DNA binding protein 43 kDa pathology were older at disease onset and had lower median MMSE scores; however, the latter was driven by concurrent pathologies. Conclusions: Distribution and clinical characteristics of transactive response DNA binding protein 43 kDa pathology in PSP were influenced by concurrent pathologies. This is the first study to observe that PSPvulnerable regions are also susceptible to this non-tau pathology. V C 2016 International Parkinson and Movement Disorder Society.
are strongly associated with memory loss. 21, 22 Taken together, the regional pattern of TDP-43 pathology is a significant factor in driving clinical phenotypes of both primary (i.e., ALS and FTLD) and secondary (i.e., AD) TDP-43 proteinopathies. 23 There are few studies describing TDP-43 pathology in PSP, but most are small series. Although several studies reported no TDP-43 pathology in PSP, 1, 10, 24 one study showed 26% (5 of 19) of PSP cases had TDP-43 pathology in the limbic system and temporal lobes. 15 Thus, the frequency of TDP-43 pathology in PSP remains uncertain.
Recent studies have identified genetic variants associated with TDP-43 pathology. The TMEM106B rs3173615 minor allele, which is associated with level of progranulin (GRN), 25 is reported to be protective for FTLD with TDP-43 inclusions (FTLD-TDP). 26, 27 The GRN rs5848 variant, whose T allele is associated with lower progranulin expression, is also reported to be a risk factor for FTLD-TDP. 28 Additionally, common variants in TMEM106B serve as distinct risk factors for TDP-43 pathology not only in FTLD patients, but also in elderly subjects without FTLD. 29 No information is available on genetic associations of TDP-43 pathology in PSP.
The aims of this study were to determine the frequency and distribution of TDP-43 pathology in PSP, the clinical features of PSP patients with TDP-43 pathology (PSP-TDP), and genetic risk factors for TDP-43 pathology. To accomplish our aims, we assessed the pathological, clinical, and genetic features of a large cohort of PSP patients.
Subjects and Methods

Case Selection
Between 2000 and 2014, 982 cases in the Mayo Clinic brain bank have been given a neuropathological diagnosis of PSP. Of the 982 PSP cases, 945 cases with available paraffin-embedded tissue and medical documentation were included in this study.
Brain autopsies were obtained after consent of the legal next of kin or individuals with legal power of attorney, and studies of autopsy samples are considered exempt from human subject research by the Mayo Clinic Institutional Review Board.
Neuropathological Assessment
One neuropathologist (D.W.D.) made all neuropathological diagnoses. The neuropathological protocol includes assessment of AD-type pathology with assignment of Braak neurofibrillary tangle (NFT) stage and Thal amyloid phase by thioflavin S fluorescent microscopy. [30] [31] [32] Neuropathological diagnosis of AD was based on the consensus criteria for the neuropathological diagnosis of AD. 33 In this study, both high and intermediate likelihood cases were diagnosed with AD. Immunohistochemistry for phospho-tau (CP13, 1:1000, from Dr. Peter Davies, Feinstein Institute, North Shore Hospital, NY) was used to establish neuropathological diagnosis of PSP. 34 The regional tau burden, including pretangles/NFT, coiled bodies, tufted astrocytes, and tau-positive threads, was graded semiquantitatively on a 4-point scale (0 5 absent, 1 5 sparse, 2 5 moderate, and 3 5 frequent). 35 Select sections were processed for Gallyas silver stain and immunohistochemistry for 4-repeat tau (RD4, 1:5,000; Millipore, Temecula, CA) to assist in neuropathological diagnosis of AGD. 36 HpScl was assessed by hematoxylin and eosin staining. HpScl was defined as neuronal loss and gliosis in hippocampal CA1 and subiculum in the absence of other pathological findings that could account for neuronal loss in these regions.
TDP-43 Immunohistochemistry
The screening for TDP-43 pathology was performed in two phases. In the first phase, 945 cases of pathologically confirmed PSP were screened for TDP-43 pathology using sections of the hippocampus at the level of subthalamic nucleus (STN). The antibody used (MC2085, 1:3,000, from Dr. Leonard Petrucelli, Mayo Clinic, Jacksonville, FL) is a phosphorylationindependent, rabbit polyclonal antibody to a neoepitope in the midregion of TDP-43 that has high specificity for pathological TDP-43. All staining was done using a Dako Autostainer (Universal Staining System; Dako, Carpinteria, CA) to assure uniformity. 37 The following regions were further screened in cases with positive hippocampal TDP-43 pathology: entorhinal cortex; amygdala at the level of the anterior commissure; medial occipitotemporal gyrus; middle frontal gyrus; putamen; globus pallidus (GP); STN; substantia nigra (SN); internal capsule; pontine tegmentum including locus coeruleus; and cerebellar dentate nucleus. All slides were reviewed simultaneously by two observers (D.W.D., S.K.) who agreed on the presence of TDP-43 immunoreactivity, defined as neuronal cytoplasmic inclusion (NCI), dystrophic neurites (DNs), fine neurites, neuronal intranuclear inclusion (NII), perivascular inclusion, or coiled body-like inclusion in any region. Severity of TDP-43 deposition was graded semiquantitatively on a 5-point scale (0 5 absent, 1 5 scant, 2 5 sparse, 3 5 moderate, and 4 5 frequent) as shown in Supporting Figure 1 .
In the second phase, 261 of the 945 cases in which no TDP-43 was detected in the hippocampus were screened for TDP-43 pathology using the amygdala as the region of interest. The amygdala was chosen because it has been shown to be one of the most vulnerable regions to TDP-43 pathology in AD, LBD, and cognitively normal elderly individuals. 5, 7, 18, 20, 38 The choice of cases from the second phase of screening included all cases with
concurrent AD (n 5 63), cases having Braak NFT stage 4 or greater (n 5 17), PSP with concurrent HpScl (n 5 1), and 180 randomly chosen cases with in which amygdala sections were available.
Clinical Assessment
We assessed clinical information in all PSP-TDP cases and a subset of TDP-43-negative PSP cases (N 5 88). The latter group was described as the Mayo Clinic patient series in our previous reports. 35 Ante-mortem clinical information for age at onset, clinical diagnosis, cognitive impairment, the last available Mini-Mental State Examination (MMSE) scores, and the duration between MMSE performed and death were gathered from clinical reports and/or a brain bank questionnaire filled out by a close family member. Patients were considered to have cognitive impairment if at least shortterm memory loss, disorientation, or executive dysfunction were diagnosed by a physician, or there were recorded complaints of these symptoms by the patient or their family members. 39 
Genetic Assessment
We performed genetic assessment in PSP cases with available frozen brain tissues: all 56 PSP-TDP cases and 844 PSP cases without TDP-43 pathology. For genotyping, genomic DNA was extracted from cerebellum of frozen brain tissue using standard procedures. Genotyping for GRN (single-nucleotide polymorphism [SNP] rs5848 C/T SNPs, T minor allele) TMEM106B (rs3173615 C/G SNPs, G minor allele), and MAPT H1/H2 (SNP rs1052553 A/G, A 5 H1, G 5 H2) was assessed with TaqMan SNP genotyping assays (Applied Biosystems, Foster City, CA) as previously reported. 26, [40] [41] [42] Genotype calls were obtained with SDS v2.2.2 software (Applied Biosystems).
Statistical Analysis
All statistical analyses were performed using SigmaPlot software (version 12.3; Systat Software, Inc., San Jose, CA). A chi-square test or Fisher's exact test was performed for group comparisons of categorical data, as appropriate. The t test or Mann-Whitney rank-sum test was used for analyses of continuous variables, as appropriate. P values < 0.05 were considered statistically significant. Multivariable logistic regression models were built for each combination of the pathological groups using the significant pathological and clinical variables from univariate analyses. In total, 56 cases were discovered to have TDP-43 pathology in either the hippocampus or amygdala, or both. Table 1 shows demographic and pathological features for all subjects. PSP-TDP cases had an older age at death than PSP cases without TDP-43 pathology (81 vs. 74; P < 0.001). Median Braak NFT stage and Thal amyloid phase were higher in PSP-TDP compared to PSP (III vs. II, P < 0.001; 3 vs. 1, P < 0.001, respectively). Frequency of concurrent AD, HpScl, and AGD was higher in PSP-TDP than in PSP (39% vs. 7%, P < 0.001; 18% vs. 0.1%, P < 0.001; 46% vs. 25%, P < 0.001, respectively). Associations of TDP-43 pathology with the presence of concurrent AD, HpScl, and AGD, as well as age at death, were assessed by a multiple logistic regression model. PSP-TDP cases had older age at death compared to PSP cases without TDP-43 pathology (odds ratio [ 
Genetic Assessment
To determine whether reported genetic risk variants for FTLD-TDP could contribute to TDP-43 pathology in PSP-TDP, we performed genetic analyses in 56 PSP-TDP and 844 PSP cases ( Table 1) . Frequency of homozygous minor allele of TMEM106b, GRN, MAPT H1/H1 genotype, and MAPT H1 haplotype was not significantly different between the two groups. Table 2 summarizes clinical characteristics and frequency of concurrent pathology of PSP-TDP and a subset of PSP cases. Age at onset was older in PSP-TDP cases than PSP cases (75 vs. 66; P < 0.001), but disease duration was not different between the two groups. Frequency of cognitive impairment was not different between the two groups, but the median score of MMSE was lower in PSP-TDP than PSP cases (20 vs. 25; P 5 0.003), despite the same median duration between MMSE performed and death (3 years). Same as the parent population of TDP-negative PSP (Table 1) , these 88 PSP cases had less concurrent HpScl, AD, or AGD. The hypothesis that differences in clinical characteristics were driven by concurrent pathology was assessed by a multiple logistic regression model. PSP-TDP cases had older age at onset Genetic analysis was performed for PSP-TDP (N 5 56) and PSP (N 5 844), respectively. One case was not available for TMEM106B. ). In contrast, the association of the presence of cognitive impairment was not independently associated with TDP-43 pathology (P 5 0.988).
Clinical Assessment
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Regional Tau Burden
To clarify the association of TDP-43 and regional tau burden, we performed immunohistochemistry for phospho-tau in all PSP-TDP cases (N 5 56) and a subset of PSP cases (N 5 88). The regional tau burden in medial temporal lobe (i.e., hippocampus and amygdala) was greater in PSP-TDP than in PSP, but no difference was found in PSP-vulnerable regions ( Table 2) .
Influence of Concomitant Pathology
To exclude the influence of concomitant pathology, we defined "pure" PSP-TDP as PSP-TDP cases without AD, HpScl, or AGD. Fifteen cases were identified as "pure" PSP-TDP. Compared to pure PSP TDP-43-negative cases (N 5 57), age at onset and death were both greater in pure PSP-TDP than in pure PSP; however, other clinical characteristics were not significantly different between the two groups (Supporting Table 1 ). This result is consistent with the results of multiple logistic regression models performed above, and suggests that these clinical characteristics of are driven by concomitant pathology. Regional tau burden was not different in medial temporal lobe and in PSP-vulnerable regions between the two groups.
Morphology of TDP-43 Pathology
A range of morphological lesions were TDP-43 immunopositive (Fig. 1) , with lesions in both neurons and glia. NCIs were most frequent and observed in all 56 TDP-43-positive cases. Most cases had a mixture of NCIs and short DNs in the hippocampus or adjacent cortices (Fig. 1A) . Ten cases had numerous NCIs with minimal DNs (Fig. 1B) . TDP-43-immunoreactive fine neurites were observed in CA1 and subiculum of 25 cases (Fig. 1C) . The NCIs were morphologically heterogeneous, including round, crescent, ring-shaped, Pick body-like, and NFT-like inclusions (Fig. 1D-F) . Only a few had skein-like morphology. Thirteen cases had NIIs in CA2, CA1, subiculum, dentate gyrus, amygdala, putamen, GP, SN, or medial occipitotemporal gyrus (Fig. 1G-I) . Two cases had perivascular TDP-43 inclusions characterized by small, globular, dense structures in close proximity to small vessels in 
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CA1 and subiculum (Fig. 1J) . Coiled body-like glial inclusions were observed in the internal capsule (Fig.  1K) . It is noteworthy that regions vulnerable to tau pathology and neuronal loss in PSP, including the SN, GP, putamen, and STN, were also frequently affected; 57% in stage II, 91% in stage III, and 90% in stage IV showed involvement in at least one PSP-vulnerable region.
Distribution of TDP-43 Pathology
Supporting Table 2 compares clinicopathological findings between early (i.e., stage A, I, and II) and late (i.e., stage III and IV) stages. Frequency of HpScl and having NIIs in late stages was significantly higher than that observed in early stages. Severity of TDP-43 pathology in late stages was higher than that in early stages in PSP-vulnerable regions. Median MMSE score was lower in late stages than that in early stages. Intriguingly, severity of AD pathology in stage IV was less than earlier stages; only 3 of 10 (30%) stage IV cases had Braak stage greater than II, although 36 of 46 (78%) stage A to III cases had.
Discussion
In a large cohort of 945 patients with pathologically confirmed PSP, we identified 47 (5%) with TDP-43 immunoreactivity in the hippocampus. We also screened 261 amygdala sections for cases with no hippocampal TDP-43 and identified 9 additional cases with isolated amygdala pathology (5 of 61 in AD [ 
8.2%] and 4 of 180 in the remaining cases [2.2%]).
Based on these results, the expected number of cases with isolated amygdala pathology in the remaining 637 cases is estimated to be 14 (2.2% of 637 cases) because no cases with concurrent AD or HpScl were included in these 637 cases. We estimate therefore that frequency of TDP-43 pathology in PSP is at least 7% in this cohort, because if different sections such as SN and STN are screened, more TDP-43-positive cases might also be identified. Frequency of TDP-43 in PSP is lower than that previously reported. 15 The discrepancy between the two studies might be attributed to the different profile of cases with concurrent pathology. Although the frequency of AD was not described, HpScl was observed in 16% of all PSP cases in Yokota and colleagues' study in comparison to 1% in our study. Different sample sizes, with the Yokota and colleagues study based on only 19 PSP cases, may also contribute differences.
The five stages of TDP-43 progression in PSP fit better with staging proposed for AD than staging of ALS or FTLD. Our staging of PSP-TDP builds upon AD staging proposed by Josephs and colleagues, 20 with some modifications. The similarities of distribution of TDP-43 pathology in AD and PSP may be explained by concurrent AD pathology in PSP-TDP. Although the amygdala was the most frequently affected site followed by the hippocampus, it is hard to determine which region is affected first because 9 cases had isolated TDP-43 pathology in amygdala whereas 5 had it only in the hippocampus and entorhinal cortex. It suggests that the progression pattern of TDP-43 pathology is heterogeneous. This study used a two-phase screening process, with only the first evaluating all 945 cases. In a subset of 261 cases with no hippocampal TDP-43, the amygdala was screened. For these reasons, we separated 9 cases with isolated TDP-43 pathology in the amygdala (stage A) from other PSP-TDP cases (stage I-IV), and then we designated the former as Stage A, given that Braak and colleagues defined Pretangle Stage a to c in a follow-up study that revealed earlier stages of Braak NFT stage. 43 A major difference in staging of TDP-43 pathology between AD and PSP-TDP is involvement of PSPvulnerable regions, including basal ganglia. In contrast to AD, in which basal ganglia are rarely affected (6%), 20 PSP-TDP cases more often had TDP-43 pathology in the basal ganglia (34%). PSP-vulnerable regions were not always assessed in other neurodegenerative diseases 3, 4, 20 ; however, a study on behavioral variant frontotemporal dementia showed that only 8% in the SN and 0% in GP were affected. 4 Kouri and colleagues described TDP-43 pathology in CBD cases; it was predominantly detected in the diencephalon and basal ganglia in typical CBD. 19 Furthermore, CBD with olivopontocerebellar atrophy, a variant of M  PSP  III  3  1 1  1  3  2  3  4  2  0  2  0  0  2 0 0  0  40 83  88  F  PDD  III  0  1  4  2  4  2  2  0  1  0  0  0 2 2  0  III  41 74  81  F  PSP  IV  5  1  4  2  2  2  3  0  2  0  2  2 
CBD, had TDP-43 pathology with a predilection for the olivopontocerebellar system. 19 The results of both Kouri and colleagues' study and our current study suggest disease-specific vulnerability to TDP-43 pathology in CBD and PSP.
Our study disclosed several risk factors for TDP-43 pathology in PSP: older age at onset and death and the presence of AD, HpScl, or AGD, as previously reported. [6] [7] [8] 14, 15, 18 Concurrent AD pathology also influenced the distribution pattern of TDP-43 
pathology in PSP, as we discussed above. The high frequency of cognitive impairment and low frequency of an antemortem clinical diagnosis of PSP were driven by the presence of AD, HpScl, and AGD. To exclude the influence of concurrent pathologies, we defined "pure PSP-TDP" (N 5 15) as PSP-TDP without AD, HpScl, or AGD. Clinical and pathological findings were not different between the two groups, so differences observed in PSP-TDP are likely driven by concomitant pathology. Age at onset and death were older in "pure" PSP-TDP than "pure" PSP. This result is consistent with a recent study in which TDP-43 pathology was proposed to be a consequence of aging. 44 Intriguingly, 9 of 15 "pure" PSP-TDP cases had extension of TDP-43 pathology to PSP-vulnerable regions, which are not affected by aging. It suggests that not only aging, but also PSP-related factors influence distribution of TDP-43 pathology in PSP.
We found that regional tau burden in the medial temporal lobe was greater in PSP-TDP than PSP. This result is consistent with Yokota and colleagues' study showing that tau burden in PSP-TDP tended to be greater than in TDP-negative PSP in the medial temporal lobe. 15 It is likely that the high frequency of AD (as well as AGD) in PSP-TDP contributes to greater tau burden in medial temporal lobe, which is supported by studies of pure PSP-TDP (Supporting Table  1 ). Specifically, when PSP with concurrent AD, AGD, or HpScl are excluded, regional tau burdens in medial temporal lobes are no longer greater in PSP-TDP. We further assessed the tau burden in PSP-vulnerable regions, but the tau burden was not significantly different between the two groups. Therefore, we conclude that no interaction between the regional tau burden and TDP-43 pathology in PSP. This fits with observations of TDP-43 in FTLD and ALS. 45 Genetic analyses in our study were at variance with previous studies of TDP-43 in other neurodegenerative diseases. No statistically significant differences were found between PSP-TDP and PSP for TMEM106B rs3173615, GRN, and MAPT. The small sample size of the PSP-TDP group may contribute to this difference.
There are some limitations of our study. First, we screened sections of the anterior hippocampus for TDP-43 pathology in all cases, but the result of the phase 2 screening, which was based on only a subset of 261 cases, suggested that some cases have TDP-43 pathology confined to amygdala. Because not all sections of amygdala were screened in phase 2, the frequency of the TDP-43 pathology in PSP may be an underestimate. We suspect, however, that the discrepancy between the estimated frequency and the actual frequency of TDP-43 in PSP might be small, if present at all, because our validation cohort included high-risk cases such as those with concurrent pathology of AD and HpScl. Another limitation is that the staging scheme is biased by the screening sites. We observed that PSP-vulnerable regions, such as the SN or internal capsule, may be affected, and it is theoretically possible that had these regions been screened in all cases, the frequency of PSP-TDP would differ.
Given the retrospective nature of this study, clinical information was limited. To evaluate possible clinical correlates of TDP-43 pathology and validate the TDP-43 staging scheme, it will be important to evaluate PSP patients who come to autopsy form prospective, clinical studies. To extract pertinent clinical information, we selected 88 PSP cases without TDP-43 pathology from the Mayo Clinic patient series. This might cause a selection bias because complicated cases tend to be referred to specialty clinics; however, demographic features and frequency of concurrent pathology were not different between these 88 cases and the rest of the PSP cases.
A notable strength of our study is the number of patients with PSP screened for TDP-43 pathology, which is many fold greater than any previous study. The estimated frequency of PSP-TDP was only 7%, and we have identified five stages of TDP-43 pathology in PSP. The progression pattern of TDP-43 in PSP closely resembles that observed in AD more than that of ALS or FTLD. The distribution of TDP-43 pathology and clinical characteristics were influenced by concurrent pathologies, including AD, HpScl, and AGD; however, we observed, for the first time, that PSP-vulnerable regions were also susceptible to TDP-43 pathology.
